Rivaroxaban and Apixaban Reduce Hemorrhagic Transformation After Thrombolysis by Protection of Neurovascular Unit in Rat

BACKGROUND AND PURPOSE—This study aimed to assess the risk and benefit of tissue-type plasminogen activator treatment after oral anticoagulation with rivaroxaban or apixaban compared with warfarin or placebo. METHODS—Pretreatment with warfarin (0.2 mg/kg per day), rivaroxaban (2 mg/kg per day), apix...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Stroke (1970) 2014-08, Vol.45 (8), p.2404-2410
Hauptverfasser:	Kono, Syoichiro, Yamashita, Toru, Deguchi, Kentaro, Omote, Yoshio, Yunoki, Taijun, Sato, Kota, Kurata, Tomoko, Hishikawa, Nozomi, Abe, Koji
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Anticoagulants - pharmacology Anticoagulants - therapeutic use Biological and medical sciences Blood Coagulation - drug effects Brain - drug effects Brain Ischemia - drug therapy Fibrinolytic Agents - adverse effects Fibrinolytic Agents - therapeutic use Intracranial Hemorrhages - etiology Intracranial Hemorrhages - prevention & control Male Medical sciences Morpholines - pharmacology Morpholines - therapeutic use Neurology Neuropharmacology Neuroprotective agent Pharmacology. Drug treatments Pyrazoles - pharmacology Pyrazoles - therapeutic use Pyridones - pharmacology Pyridones - therapeutic use Rats Rats, Wistar Rivaroxaban Stroke - drug therapy Thiophenes - pharmacology Thiophenes - therapeutic use Thrombolytic Therapy - adverse effects Tissue Plasminogen Activator - adverse effects Tissue Plasminogen Activator - therapeutic use Vascular diseases and vascular malformations of the nervous system
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!